Insilico Medicine has entered into a significant collaboration with Eli Lilly to leverage AI technologies for drug discovery across various therapeutic areas. This partnership, announced on March 29, 2026, grants Lilly an exclusive worldwide license for developing novel oral therapeutics currently in preclinical stages. Insilico is set to receive an $115 million upfront payment, with potential milestones bringing the total deal value to approximately $2.75 billion, plus royalties on future sales. Insilico’s CEO emphasized the transformative potential of AI in creating solutions for high unmet medical needs.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.lelezard.com/en/news-22167423.html
